1.50Open1.50Pre Close0 Volume136 Open Interest9.00Strike Price0.00Turnover93.26%IV-6.33%PremiumJan 17, 2025Expiry Date2.21Intrinsic Value100Multiplier14DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9038Delta0.0834Gamma4.82Leverage Ratio-0.0133Theta0.0030Rho4.36Eff Leverage0.0037Vega
Omeros Stock Discussion
how long will the hold off volume before reaching above 30
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet